[go: up one dir, main page]

SMT201600103B - Composti per sopprimere un disturbo di un nervo periferico indotto da un agente anti-cancro - Google Patents

Composti per sopprimere un disturbo di un nervo periferico indotto da un agente anti-cancro

Info

Publication number
SMT201600103B
SMT201600103B SM201600103T SM201600103T SMT201600103B SM T201600103 B SMT201600103 B SM T201600103B SM 201600103 T SM201600103 T SM 201600103T SM 201600103 T SM201600103 T SM 201600103T SM T201600103 B SMT201600103 B SM T201600103B
Authority
SM
San Marino
Prior art keywords
disorder
save
compounds
cancer agent
peripheral nerve
Prior art date
Application number
SM201600103T
Other languages
English (en)
Inventor
Naomi Kitamoto
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43770309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201600103(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of SMT201600103B publication Critical patent/SMT201600103B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/28—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SM201600103T 2010-01-27 2016-04-12 Composti per sopprimere un disturbo di un nervo periferico indotto da un agente anti-cancro SMT201600103B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010015935 2010-01-27
PCT/JP2011/052077 WO2011093512A1 (en) 2010-01-27 2011-01-26 Compounds for suppressing a peripheral nerve disorder induced by an anti - cancer agent

Publications (1)

Publication Number Publication Date
SMT201600103B true SMT201600103B (it) 2016-04-29

Family

ID=43770309

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201600103T SMT201600103B (it) 2010-01-27 2016-04-12 Composti per sopprimere un disturbo di un nervo periferico indotto da un agente anti-cancro

Country Status (41)

Country Link
US (5) US20130046000A1 (it)
EP (1) EP2528598B1 (it)
JP (2) JP6131046B2 (it)
KR (1) KR20120118044A (it)
CN (2) CN104744321A (it)
AR (1) AR080024A1 (it)
AU (1) AU2011211294B2 (it)
BR (1) BR112012018434A2 (it)
CA (1) CA2788150C (it)
CL (1) CL2012002079A1 (it)
CO (1) CO6592110A2 (it)
CR (1) CR20120412A (it)
CY (1) CY1117268T1 (it)
DK (1) DK2528598T3 (it)
DO (1) DOP2012000209A (it)
EA (1) EA201290697A1 (it)
EC (1) ECSP12012126A (it)
ES (1) ES2560215T3 (it)
GE (1) GEP20166441B (it)
HR (1) HRP20160165T1 (it)
HU (1) HUE027310T2 (it)
IL (1) IL221066A (it)
MA (1) MA34014B1 (it)
ME (1) ME02364B (it)
MX (1) MX2012008514A (it)
MY (1) MY163936A (it)
NZ (1) NZ601635A (it)
PE (1) PE20121694A1 (it)
PH (1) PH12012501538A1 (it)
PL (1) PL2528598T3 (it)
PT (1) PT2528598E (it)
RS (1) RS54591B1 (it)
SG (2) SG182522A1 (it)
SI (1) SI2528598T1 (it)
SM (1) SMT201600103B (it)
TN (1) TN2012000364A1 (it)
TW (1) TWI481401B (it)
UA (1) UA109540C2 (it)
UY (1) UY33203A (it)
WO (1) WO2011093512A1 (it)
ZA (1) ZA201205681B (it)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9428477B2 (en) 2012-04-27 2016-08-30 Nippon Zoki Pharmaceutical Co., Ltd. Trans-2-decenoic acid derivative and drug containing same
SG10201808519VA (en) * 2013-12-17 2018-10-30 Genentech Inc Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies
CA2985325C (en) 2015-05-08 2023-09-26 Takeda Pharmaceutical Company Limited Cyclic compounds for inhibition of toll-like receptor 4
EP3310815A1 (en) 2015-06-17 2018-04-25 F. Hoffmann-La Roche AG Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
US10738004B2 (en) 2016-09-09 2020-08-11 Takeda Pharmaceutical Company Limited Cyclic compound
WO2019047812A1 (zh) * 2017-09-07 2019-03-14 深圳信立泰药业股份有限公司 多西他赛共缀物的药物组合物及制备方法

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804374A (en) 1980-12-05 1998-09-08 Massachusetts Insti. Technology Nuclear factors associates with transcriptional regulation
US6410516B1 (en) 1986-01-09 2002-06-25 President & Fellows Of Harvard College Nuclear factors associated with transcriptional regulation
EP0252146B1 (en) 1986-01-09 1994-05-25 Massachusetts Institute Of Technology Nuclear factors associated with transcriptional regulation
US4769372A (en) 1986-06-18 1988-09-06 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
US4785000A (en) 1986-06-18 1988-11-15 The Rockefeller University Method of treating patients suffering from chronic pain or chronic cough
WO1988005083A1 (en) 1986-12-24 1988-07-14 Whitehead Institute For Biomedical Research Method of inducible gene expression
WO1989007614A1 (en) 1988-02-12 1989-08-24 Massachusetts Institute Of Technology Nuclear factors associated with transcriptional regulation
EP0407411B1 (en) 1988-03-01 1993-11-10 Whitehead Institute For Biomedical Research ACTIVITION OF NF-kB PRECURSOR
US5506231A (en) 1989-03-31 1996-04-09 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
JP3479532B2 (ja) 1989-03-31 2003-12-15 ザ・チルドレンズ・メディカル・センター・コーポレーション エイズの痴呆症、脊髄障害および失明の治療
US5334618A (en) 1991-04-04 1994-08-02 The Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5059712A (en) 1989-09-13 1991-10-22 Cornell Research Foundation, Inc. Isolating aminoarginine and use to block nitric oxide formation in body
US5158883A (en) 1989-09-13 1992-10-27 Cornell Research Foundation, Inc. Method of using aminoarginine to block nitric oxide formation in vitro
JPH06500554A (ja) 1990-08-23 1994-01-20 ザ・チルドレンズ・メディカル・センター・コーポレイション エイズ性痴呆、脊髄障害、末梢神経障害、および視覚喪失の治療
WO1992017168A1 (en) 1991-04-04 1992-10-15 The Children's Medical Center Corporation Method of preventing nmda receptor-mediated neuronal damage
US5455279A (en) 1991-04-19 1995-10-03 The Children's Medical Center Corporation Regimen method of mediating neuronal damage using nitroglycerine
US5614560A (en) 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
EP0581856B1 (en) 1991-04-19 1999-07-14 The Children's Medical Center Corporation Method of preventing nmda receptor complex-mediated neuronal damage
US6071876A (en) 1991-04-19 2000-06-06 Children's Medical Center Corporation Method of preventing NMDA receptor complex-mediated neuronal damage
CA2224103A1 (en) * 1995-06-07 1996-12-19 Sugen, Inc. Method and compositions for inhibition of adaptor protein/tyrosine kinase interactions
US20020052019A1 (en) 1997-11-13 2002-05-02 Genentech Inc Human toll homologue
US20030032090A1 (en) 1997-05-07 2003-02-13 Schering Corporation, A New Jersey Corporation Human receptor proteins; related reagents and methods
ZA989147B (en) 1997-10-17 2000-04-07 Genentech Inc Human toll homologues.
PT1650219E (pt) 1997-10-17 2008-03-31 Genentech Inc Homólogos de toll humana
US20040072138A1 (en) 1997-11-25 2004-04-15 Medical University Of South Carolina Attenuation of ischemia/reperfusion injury
WO1999026657A1 (en) 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
US20080275104A1 (en) 1997-11-25 2008-11-06 Musc Foundation For Research Development Methods of treating juvenile type 1 diabetes mellitus
CA2311642A1 (en) 1997-11-25 1999-06-03 Princeton University Method for preparing adenovirus vectors, vectors so prepared, and uses thereof
RU2214398C2 (ru) 1998-03-09 2003-10-20 Такеда Кемикал Индастриз, Лтд. Производное циклоалкена, способ его получения (варианты), фармацевтическая композиция, способ ингибирования, способ профилактики или лечения
CA2380990A1 (en) 1999-08-06 2001-02-15 Takeda Chemical Industries, Ltd. Substituted aromatic-ring compounds, process for producing the same, and use
SE9903930D0 (sv) * 1999-10-29 1999-10-29 Astra Pharma Inc Novel compounds and a novel process for their preparation
KR100784752B1 (ko) 2000-02-04 2007-12-13 다케다 야쿠힌 고교 가부시키가이샤 안정한 에멀젼 조성물
NZ522327A (en) 2000-05-25 2004-09-24 Schering Corp Mammalian DNAX Toll-like receptor protein, DTLR 10, antibodies and medicaments made therefrom and use in treating immunological disorders
US6951885B2 (en) 2000-08-10 2005-10-04 Takeda Pharmaceutical Company Limited Pharmaceutical composition
US6982344B2 (en) 2000-10-18 2006-01-03 Takeda Pharmaceutical Company Limited Process for preparation of optically active sulfonamides and intermediates for their synthesis
JP4498678B2 (ja) 2000-11-30 2010-07-07 株式会社トクヤマ 基板およびその製造方法
US20040063685A1 (en) 2000-12-08 2004-04-01 Juji Ilzawa Combination Drugs
US7960416B2 (en) 2001-08-03 2011-06-14 Takeda Pharmaceutical Company Limited Stable emulsion composition
WO2003084527A1 (en) 2002-04-08 2003-10-16 Takeda Chemical Industries, Ltd. Severe sepsis preventive therapeutic agent
US8710095B2 (en) 2002-04-30 2014-04-29 Bionumerik Pharmaceuticals, Inc. Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity
US20040259790A1 (en) 2003-01-30 2004-12-23 Bali Pulendran Methods for identifying and administering agents that bias the immune response via dendritic cells
US7485432B2 (en) 2003-02-27 2009-02-03 3M Innovative Properties Company Selective modulation of TLR-mediated biological activity
US20040191833A1 (en) 2003-03-25 2004-09-30 3M Innovative Properties Company Selective activation of cellular activities mediated through a common toll-like receptor
US20050059072A1 (en) 2003-09-17 2005-03-17 3M Innovative Properties Company Selective modulation of TLR gene expression
US7927873B2 (en) 2003-12-19 2011-04-19 University Of Cincinnati Polyamides for nucleic acid delivery
MY147790A (en) 2005-04-28 2013-01-31 Takeda Pharmaceutical Stable emulsion composition
CN101237885B (zh) 2005-06-03 2011-01-19 小野药品工业株式会社 神经再生和/或保护剂
US7618982B2 (en) 2005-12-19 2009-11-17 Nerviano Medical Sciences S.R.L. Heteroarylpyrrolopyridinones active as kinase inhibitors
US20090175835A1 (en) 2006-02-07 2009-07-09 Korea Institute Of Radiological & Medical Sciences Composition for treating damage of central or peripheral nerve system
ATE524732T1 (de) 2006-02-23 2011-09-15 Univ Yale Wirkstoffresistenz gegen pflanzenalkaloide basieren auf dem myd88-status in einer zelle und verfahren zum hemmen der signalgebung durch den tlr-4:myd88-signalweg
US7943588B2 (en) 2006-03-28 2011-05-17 Trustees Of Dartmouth College Method for preventing or treating neuropathic pain
US8329420B2 (en) 2006-03-30 2012-12-11 Hiroshima University Screening method for a substance that binds to an intracellular region of TLR4
EP2018872A4 (en) * 2006-04-20 2010-06-09 Takeda Pharmaceutical PHARMACEUTICAL PRODUCT
WO2007132825A1 (ja) 2006-05-15 2007-11-22 Takeda Pharmaceutical Company Limited 医薬
JPWO2008004673A1 (ja) 2006-07-07 2009-12-10 武田薬品工業株式会社 シクロアルケン誘導体、その製造法および用途
EP1882687A1 (en) * 2006-07-27 2008-01-30 Amorepacific Corporation Heterocyclic compounds useful as vanilloid receptor antagonists and pharmaceutical compositions containing the same
WO2008112887A1 (en) 2007-03-13 2008-09-18 Musc Foundation For Research Development Methods of treating juvenile type 1 diabetes mellitus
US8399421B2 (en) 2007-03-30 2013-03-19 The Board Of Regents Of The University Of Texas System Treatment for neuropathic pain due to spinal cord injury
WO2009059050A2 (en) 2007-10-30 2009-05-07 The Regents Of The University Of Colorado Tlr modulators and methods for using the same
EP2262498A2 (en) 2008-03-10 2010-12-22 Vertex Pharmceuticals Incorporated Pyrimidines and pyridines useful as inhibitors of protein kinases
JP5238381B2 (ja) 2008-07-07 2013-07-17 スタンレー電気株式会社 照明用車両用灯具
EP2480536B1 (en) 2009-09-23 2014-08-13 The Regents of the University of Colorado, A Body Corporate Toll-like receptor modulators and uses thereof

Also Published As

Publication number Publication date
RS54591B1 (sr) 2016-08-31
PH12012501538A1 (en) 2015-11-09
JP6131046B2 (ja) 2017-05-17
SG10201503402XA (en) 2015-06-29
CY1117268T1 (el) 2017-04-26
US20160166526A1 (en) 2016-06-16
CN102821763A (zh) 2012-12-12
IL221066A (en) 2016-10-31
DOP2012000209A (es) 2012-12-31
CA2788150C (en) 2017-06-06
ZA201205681B (en) 2013-09-25
PT2528598E (pt) 2016-03-04
NZ601635A (en) 2013-06-28
US20130046000A1 (en) 2013-02-21
UY33203A (es) 2011-08-31
WO2011093512A1 (en) 2011-08-04
UA109540C2 (uk) 2015-09-10
CL2012002079A1 (es) 2012-12-21
TW201130482A (en) 2011-09-16
BR112012018434A2 (pt) 2016-04-19
ES2560215T3 (es) 2016-02-17
CN104744321A (zh) 2015-07-01
CA2788150A1 (en) 2011-08-04
EP2528598A1 (en) 2012-12-05
TWI481401B (zh) 2015-04-21
DK2528598T3 (en) 2016-03-07
KR20120118044A (ko) 2012-10-25
AU2011211294B2 (en) 2014-11-13
CR20120412A (es) 2012-11-13
HK1177423A1 (zh) 2013-08-23
MA34014B1 (fr) 2013-02-01
US20150203464A1 (en) 2015-07-23
SG182522A1 (en) 2012-08-30
CN102821763B (zh) 2017-09-22
HUE027310T2 (en) 2016-10-28
AR080024A1 (es) 2012-03-07
MX2012008514A (es) 2012-08-17
TN2012000364A1 (en) 2014-01-30
EA201290697A1 (ru) 2013-02-28
EP2528598B1 (en) 2016-01-13
CO6592110A2 (es) 2013-01-02
US8901171B2 (en) 2014-12-02
HRP20160165T1 (hr) 2016-03-11
AU2011211294A1 (en) 2012-09-20
ME02364B (me) 2016-06-20
PL2528598T3 (pl) 2016-06-30
ECSP12012126A (es) 2012-09-28
JP2016175903A (ja) 2016-10-06
US20150051256A1 (en) 2015-02-19
AU2011211294A2 (en) 2012-10-04
GEP20166441B (en) 2016-03-10
US20130345304A1 (en) 2013-12-26
JP2013518032A (ja) 2013-05-20
MY163936A (en) 2017-11-15
PE20121694A1 (es) 2012-12-06
SI2528598T1 (sl) 2016-04-29

Similar Documents

Publication Publication Date Title
GB2526932B (en) Administration of web page
IL236376B (en) Eicosapentaenoic acid ethyl ester for use as a medicament for reducing a risk of cardiovascular death
EP2878520A4 (en) BORDER CIRCUIT FOR A VEHICLE
CO7020873A2 (es) Inmunoenlazadores dirigidos contra el tnf
EP2922953A4 (en) PENTOSEFERMENTATION BY A RECOMBINANT MICROORGANISM
SMT201600103B (it) Composti per sopprimere un disturbo di un nervo periferico indotto da un agente anti-cancro
SG11201402112RA (en) Use of humanized mice to determine toxicity
EP2611451A4 (en) DESIGN OF OLIGONUCLEOTIDE ANALOGUES AS THERAPEUTIC AGENTS
EP2719760A4 (en) IMPROVED NITRIL HYDRATASE
EP2705482A4 (en) DYNAMIC ASSIGNMENT OF ADVERTISING
HRP20182043T1 (hr) Upotreba anti-konfeksinskih sredstava za poboljšanje terapijskog učinka inhibitora acetilkolinesteraze
ZA201306086B (en) Use of acetylated tubulin as a biomarker of drug response to furazanobenzimidazoles
LT2720701T (lt) Terapinis parenterinio krilių aliejaus taikymas
EP2793865A4 (en) PHARMACEUTICAL COMPOSITIONS OF TRIPTORELIN MICROBALLS
EP2716754A4 (en) IMPROVED NITRIL HYDRATASE
PT2701683T (pt) Administração de iloprost como bólus de aerossol
PL2666016T3 (pl) Zastosowanie BUBR1 jako biomarkera odpowiedzi lekowej
PT2666014T (pt) Utilização de glu-tubulina como um biomarcador da resposta farmacológica a furazanobenzimidazolos
PL2666015T3 (pl) Zastosowanie statminy jako biomarkera odpowiedzi lekowej na furazanobenzoimidazole
DK2592283T3 (da) Stikforbindelse til et møbel
TWM387309U (en) Structural improvement of mouse pad
ITTO20121147A1 (it) Microorganismo per produrre tereftalato da biomassa
GB201211721D0 (en) Improvements is or relating to urolgical catheters
EP2726505A4 (en) THERAPEUTIC TARGETING OF FICOLIN-3
EP2744835A4 (en) REDOX REACTION CURING COMPOSITIONS INITIATED BY PHOTOLYSIS